Sofinnova Partners Announces Three New Investments From Its Fund Dedicated to Italian Scientific Research
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases. The startups, AAVantgarde Bio, Alia Therapeutics, and Borea Therapeutics, are developing promising new therapies for rare, genetic diseases.
Graziano Seghezzi, Managing Partner at Sofinnova Partners, commented: “These investments mark an important step in our mission to support the excellent scientific research coming out of Italian academic and research centers. They also highlight the exceptional flow of new investment opportunities in Italian biotech, and the important role that venture capital plays in enabling ground-breaking treatments to reach patients suffering from rare, genetic diseases who today have very few therapeutic options.”
The Sofinnova Telethon Fund is the largest fund entirely dedicated to biotechnology in Italy. The team is led by technology transfer specialists Lucia Faccio and Paola Pozzi, Partners at Sofinnova Partners, who are based in the firm’s Milan office.
The three new seed investments, totaling €6M, align with the fund’s investment strategy to seek out and support the best Italian science and the most promising entrepreneurs to develop world-class companies in the field of rare, genetic diseases.
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy. The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. Existing AAV-based platforms have been limited by capacity, and AAVantgarde Bio responds to this challenge by enabling delivery of large genes to tissue and cells in vivo. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.
Alia Therapeutics, based in Trento, is developing next generation CRISPR-based medicine for safer on-target in vivo gene editing approaches to the treatment of retinal degeneration. Alia is a spin-off of the University of Trento and was accelerated at BiovelocITA, Italy’s first biotechnology accelerator co-founded in 2015 by Sofinnova Partners and two serial entrepreneurs, Silvano Spinelli and Gabriella Camboni. It is the second company to emerge from the accelerator, following the success of Enthera Pharmaceuticals, another Italian startup that is part of Sofinnova Partners’ portfolio. This round of financing also included participation from BiovelocITA, Indaco Venture Partners, and a group of Italian investors brought together by Banor SIM and Banca Profilo.
Ms. Pozzi, Partner at Sofinnova Partners, board member of AAVantgarde Bio and an investment partner in Alia Therapeutics, commented: “We are delighted to support these innovative biotech startups as they advance promising programs towards preclinical and clinical development. Both companies have highly qualified scientific teams with globally recognized expertise in the field of gene therapy and gene editing. We are confident in the potential of these companies to tackle the limitations of existing therapies and develop treatments to diseases that do not have adequate solutions today.”
Borea Therapeutics, based in Milan, is advancing a new generation of gene therapies that would enable targeting of specific tissues and cells. The company’s innovative technology could enable viral vectors to reach areas like the central nervous system (CNS) and peripheral nervous system (PNS), thus opening the door to new therapeutic options. Borea Therapeutics was co-founded by Professor Paul Heppenstall and the European Molecular Biology Lab (EMBL), an intergovernmental research organization with six research sites throughout Europe, including one in Rome. The company’s research activities are performed in collaboration with Scuola Internazionale Superiore di Studi Avanzati (SISSA), a scientific center of excellence in Trieste.
Ms. Faccio, Partner at Sofinnova Partners and a board member of Borea Therapeutics, commented: “One of the major limitations of gene therapy is the difficulty of selectively targeting specific cells or tissues. Borea Therapeutics’ technology has the potential to pinpoint specific tissues and cells, which would enable the use of lower doses, making treatment safer and more effective for patients. This could be the next breakthrough in gene therapy.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005320/en/
Contact information
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Rafaella Casula rafaella.casula@havaspr.com
+39 (0) 345 3780834
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com